|
Clinical and biochemical parameters for 167 subjects with type 2 diabetes, stratified according to cardiac function |
||||
| Total cohort (n = 167) |
Normal cardiac function (n = 59) |
Diastolic dysfunction alone (n = 66) |
Diastolic and systolic dysfunction (n = 30) |
|
|
|
||||
| Intrarenal RI |
0.69 ± 0.01 |
0.66 ± 0.06 |
0.72 ± 0.06** |
0.71 ± 0.06** |
| Age (years) |
62 ± 12 |
55 ± 13 |
66 ± 9* |
66 ± 12* |
| Sex (% male) |
59% |
59% |
54% |
72% |
| Diabetes duration (years) |
11 ± 8 |
9 ± 6 |
13 ± 8* |
10 ± 7 |
| Obese BMI (>30 kg/m2, %) |
57% |
48% |
60% |
56% |
| History of CVD (%) |
36% |
23% |
32% |
69%* |
| HbA1c (%) |
7.7 ± 1.5 |
8.1 ± 1.5 |
7.6 ± 1.3* |
7.4 ± 1.9* |
| Metformin use(%) |
68% |
80% |
55%* |
69% |
| Sulphonylurea use (%) |
57% |
62% |
50% |
72% |
| Glitazone use (%) |
19% |
31% |
11%* |
17% |
| Insulin use (%) |
42% |
45% |
46% |
24% |
| Hypertension (%) |
81% |
69% |
85%* |
90%* |
| Systolic BP (mmHg) |
140 ± 17 |
135 ± 17 |
144 ± 18 |
141 ± 15 |
| Diastolic BP (mmHg) |
75 ± 8 |
76 ± 8 |
74 ± 8 |
76 ± 9 |
| RAS inhibitor use (%) |
72% |
54% |
84%* |
83%* |
| Number of antihypertensives (n) |
1.9 ± 1.4 |
1.3 ± 1.3 |
2.1 ± 1.4* |
2.7 ± 1.5* |
| Total cholesterol (mM) |
4.7 ± 0.9 |
4.9 ± 1.0 |
4.8 ± 0.8 |
4.6 ± 1.0 |
| Triglycerides (mM) |
2.1 ± 1.2 |
2.3 ± 1.3 |
2.0 ± 1.1 |
2.3 ± 1.4 |
| Treatment for dyslipidaemia |
63% |
58% |
53% |
90%* |
| History of retinopathy |
27% |
14% |
44%* |
17% |
| iGFR (ml/min/1.73 m2) |
93 ± 32 |
111 ± 27 |
82 ± 27* |
73 ± 30* |
| GFR< 60 (ml/min/1.73 m2) |
22% |
6% |
25%* |
39%* |
| AER > 20 (μg/min) |
45% |
41% |
39% |
59%* |
|
Data for continuous variables are mean ± SD. Data for categorical variables are expressed as proportions. * p < 0.05, ** p < 0.01 vs individuals with normal cardiac function on TTE, | ||||
MacIsaac et al. Cardiovascular Diabetology 2008 7:15 doi:10.1186/1475-2840-7-15 |
||||